['migraine']
['erenumab', 'placebo']

        Inclusion Criteria:

          -  History of migraine (with or without aura) for ≥ 12 months prior to screening
             according to the International Headache Society (IHS) International Classification of
             Headache Disorders (ICHD-3) classification

          -  Migraine frequency: ≥ 4 and < 15 migraine days per month on average across the 3
             months prior to screening and during baseline

          -  Headache frequency: < 15 headache days per month on average across the 3 months prior
             to screening and baseline

          -  Demonstrated at least 80% compliance with the eDiary.

        Exclusion Criteria:

          -  Older than 50 years of age at migraine onset

          -  History of cluster headache or hemiplegic migraine headache

          -  Unable to differentiate migraine from other headache

          -  No therapeutic response with > 2 medication categories for prophylactic treatment of
             migraine after an adequate therapeutic trial

          -  Used a prohibited medication, device, or procedure within 2 months prior to the start
             of the baseline phase or during the baseline phase

          -  Concomitant use of 2 or more medications with possible migraine prophylactic effects
             within 2 months prior to the start of the baseline phase or during the baseline phase.
             If only 1 prophylactic medication is used, the dose must be stable within 2 months
             prior to the start of the baseline phase and throughout the study
      